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Abstract  
Cancer is one of the main causes of death worldwide. Chemotherapy, despite its severe 
side effects, is to date one of the leading strategies against cancer. Metal-based drugs 
present several potential advantages when compared to organic ones and gained trust 
from the scientific community after the approval on the market of the drug cisplatin. 
Recently, we reported a ruthenium complex ([Ru(DIP)2(sq)](PF6), where DIP is 4,7-
diphenyl-1,10-phenantroline and sq is the semiquinonate), with a remarkable potential 
as chemotherapeutic agent against cancer, both in vitro and in vivo. In this work, we 
analyse a structurally similar compound, namely [Ru(DIP)2(mal)](PF6), carrying the 
flavour-enhancing agent approved by the FDA, maltol (mal). To possess an FDA 
approved ligand is crucial for a complex, whose mechanism of action might include 
ligand exchange. Herein, we describe the synthesis and characterisation of 
[Ru(DIP)2(mal)](PF6), its stability in solutions and in conditions which resemble the 
physiological ones, and its in-depth biological investigation. Cytotoxicity tests on 
different cell lines in 2D model and on HeLa MultiCellular Tumour Spheroids (MCTS) 
demonstrated that our compound has higher activity compared to the approved drug 
cisplatin, inspiring further tests. [Ru(DIP)2(mal)](PF6) was efficiently internalised by 
HeLa cells through a passive transport mechanism and severely affected the 
mitochondrial metabolism.  
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Introduction  
Metal-based drugs are currently playing an essential role in the treatment of cancer.[1] 
Cisplatin, carboplatin and oxaliplatin are widely used in the clinics.[2],[3] Ruthenium 
complexes are, to date, the most promising candidates for the next generation of metal-
based drugs against cancer.[4]–[6] The Ru(III) complexes KP1019, KP1339 (referred as 
IT-139 recently) and NAMI-A have entered clinical trials as anticancer drugs,[7]–[11] 
while TLD-1433 – a substitutionally inert Ru(II) polypyridyl complex – recently 
entered phase II clinical trial as a photosensitizer for photodynamic therapy 
(PDT).[12],[13] Inert Ru polypyridyl complexes hold a tremendous potential as 
chemotherapeutic agents against cancer.[14]–[16] Recently, we reported the in-depth 
biological investigation of a very promising Ru(II) polypyridyl complex carrying a 
semiquinonate ligand ([Ru(DIP)2(sq)](PF6)) (Figure 1, DIP = 4,7-diphenyl-1,10-
phenantroline, sq = semiquinonate).[17] We could notably show that this complex had a 
much higher cytotoxicity than cisplatin in several cancer cell lines (i.e. in the nanomolar 
concentration range), and a very promising in vivo activity. Moreover, contrary to 
cisplatin, [Ru(DIP)2(sq)](PF6) results in mitochondrial dysfunction as one of its modes 
of action.[17] 
Maltol, (3-hydroxy-2-methyl-4-pyrone), belonging to the family of 2-alkyl-3-hydroxy-
4-pyrones, is structurally very similar to sq and – upon deprotonation – forms stable 5-
membered chelate rings with metal ions. Maltol is a product of carbohydrate 
degradation, which can be found in coffee, baked cereals, chicory, soybeans and other 
products.[18],[19] It possesses candy-floss, sweet flavour, and is approved by the FDA as 
a flavour-enhancing agent.[18],[20],[21] Maltol is known for its antioxidative properties[22] 
and its ability to chelate metal ions. It is an effective ligand for increasing absorption 
and bioavailability of metal ions.[23]–[33] Maltol has been tested on different human cell 
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lines, confirming lack of toxicity with IC50 (the half maximal inhibitory concentration) 
values always above 100 μM.[34],[35] In 2006, Thompson and co-workers reported a 
critical review about the applications of maltol-containing metal complexes in 
medicinal chemistry.[28] One of them concerns the restoration of iron balance in 
anaemia. The uptake of iron has indeed been proven to be significantly enhanced in the 
presence of maltol, in both in vitro and in vivo models.[36],[37] The 
bis(maltolato)oxovanadium(IV) complex developed by Orvig and co-workers (better 
known as BMOV, Figure 1) was found to have a high anti-diabetic activity as insulin 
mimetic agent, and its derivative – the orally administered 
bis(ethylmaltolato)oxovanadium(IV) (BEOV in Figure 1) – was tested in phase 
IIa.[24],[29],[38]–[41] Gallium maltolate, (tris(3-hydroxy-2-methyl-4H-pyran-4-
onato)gallium (GaM), Figure 1), recently has completed phase II clinical trials for the 
treatment of malignant lymphomas, multiple myeloma, bladder neoplasm and prostatic 
neoplasms.[42]–[45] It was found to be better orally absorbed than simple gallium salts 
(such as the chloride or nitrate).[42] This higher oral bioavailability offers the possibility 
of a more convenient and tolerable achievement of therapeutically useful blood gallium 
levels.[42],[43] The great potential demonstrated by GaM led to the investigation of other 
possible applications of this compound in medicine (e.g., treatment of Pseudomonas 
aeruginosa infection, the neglected tropical disease yaws, and other types of 
cancer).[46]–[49] Mononuclear and dinuclear maltol-containing half-sandwich 
ruthenium(II) complexes have been extensively investigated in the past decades as 
chemotherapeutic agents against cancer.[31],[33],[50],[51] However, only dinuclear species 
were found to have significant cytotoxicity toward human cancer cell lines (IC50 <10 
μM).[33],[51]  
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With this mind, in this work we present a novel Ru(II)-maltol polypyridyl complex, 
namely [Ru(DIP)2(mal)](PF6) (mal = maltolate) shown in Figure 1. To the best of our 
knowledge, [Ru(DIP)2(mal)](PF6) is the first maltol-containing ruthenium polypyridyl 
complex investigated as a chemotherapeutic agent against cancer. 
[Ru(DIP)2(mal)](PF6) is chiral and is isolated as a racemic mixture of ∆ and Λ 
enantiomers. No attempt to work with enantiopure complexes was made in this work. 
In this study, besides the synthesis and characterisation of [Ru(DIP)2(mal)](PF6), we 
report its binding to human serum albumin (HSA) and its biological activity against 
different human cancer cell lines. Due to the high cytotoxicity expressed by 
[Ru(DIP)2(mal)](PF6), additional biological studies were undertaken to obtain more 
insights about the possible targets and mechanism(s) of action of the compound. As 
described below, [Ru(DIP)2(mal)](PF6) was found to be highly cytotoxic against HeLa 
MCTS (Multicellular tumour spheroids) and to be efficiently internalised by HeLa 
cells. Its accumulation mostly in nucleus and mitochondria suggests a mechanism of 
action involving multicellular targets, which does not exclude ligand exchange at the 
metal centre.  
 
 
Figure 1. Structures of [Ru(DIP)2(sq)](PF6), [Ru(DIP)2(mal)](PF6), BMOV, BEOV 
and GaM. 
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Results and Discussion 
Synthesis and characterization of [Ru(DIP)2(mal)](PF6) 
The synthesis of [Ru(DIP)2(mal)](PF6) was achieved in two steps (Scheme 1). In the 
first step the known Ru(II) precursor RuCl2(dmso)4[52] was treated with DIP and LiCl 
in refluxing DMF to afford RuCl2(DIP)2 in 72% yield after precipitation with 
acetone.[53] The ruthenium intermediate was then refluxed in ethanol with maltol in the 
presence of NaOH for 3 h. [Ru(DIP)2(mal)](PF6) was obtained after precipitation with 
a large excess of NH4PF6 in 90% yield. The identity of the product was confirmed by 
1H and 13C NMR spectroscopy (Figure S1) as well as HR-MS, and its purity by 
microanalysis. The number of resonances showed in the 1H is consistent with the 
inequivalence of the two DIP ligands, due to the asymmetry of maltolate. 
 
Scheme 1. Synthesis of [Ru(DIP)2(mal)](PF6). a) LiCl, DMF, reflux, 24 h, 78%; b) (i) 
NaOH, maltol, ethanol, reflux, 3 h; (ii) NH4PF6, ethanol/H2O (1:10), yield: 90%. 
 
Electrochemistry 
The electrochemical properties of [Ru(DIP)2(mal)](PF6) were investigated using 
cyclic voltammetry (CV) and rotating disc electrode (RDE) voltammetry.  The RDE 
voltammogram (Figure S2) displays three well-defined wave features, in addition to 
that of decamethylferrocene used as internal reference and located at +0.090 V vs SCE. 
These electrochemical features are characterized by the same current intensity, which 
attests that the related redox processes involve the same number of electron transitions 
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(in this case one-electron transition). CV experiment (Figure S2) showed the complete 
reversibility of the redox processes. The redox potentials were assigned by comparison 
with the data reported in our recent paper on [Ru(DIP)2(sq)](PF6) (Table S1).[17] The 
process taking place at more positive potentials (+0.566 V vs SCE) can be attributed to 
the Ru(II)→Ru(III) oxidation, while the two processes at negative potentials can be 
assigned to the reduction of the ancillary ligands (DIP0/-).[54],[55] The potential associated 
to the metal oxidation of [Ru(DIP)2(mal)](PF6) is almost 100 mV lower than what was 
observed for [Ru(DIP)2(sq)](PF6) in accordance with the higher electron donating 
property of the maltolate when compared to the semiquinonate ligand. No redox 
process involving the maltol appears in the potential range investigated, which is 
completely in agreement with the literature data.[56]  
 
Solubility and Stability Studies in Different Solvents and Interaction with Human 
Serum Albumin 
The biological ability of a compound is strongly influenced by its solution stability. The 
stability of [Ru(DIP)2(mal)](PF6) was first assessed in DMSO-d6 using 1H NMR 
spectroscopy since this solvent was found to be possibly problematic during biological 
experiments.[57]–[59] The 1H NMR spectrum of [Ru(DIP)2(mal)](PF6) remained 
unchanged over 42 h at room temperature, revealing the stability of the complex in 
DMSO (Figure S3). 
[Ru(DIP)2(mal)](PF6) shows limited solubility in water and in buffered aqueous media 
like 20 mM phosphate or HEPES buffer at pH 7.40. Dilution of ethanolic stock 
solutions of the complex in phosphate or HEPES buffer (≤ 2% (v/v) ethanol, 20 M 
complex) afforded a precipitate after 1 h and 2 h, respectively, while dilution in water 
(pH ~ 8) afforded solutions that were stable at least for 6 h (Figure S4). It is important 
10.1002/chem.201904877
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
9 
 
to note that in no case decomposition of the complex (i.e. release of maltol) could be 
detected based on the UV-vis and ultrafiltration studies. Only the different rates of 
precipitation were observed by varying the type of the media (see more details in the 
SI, sections S5 and S7). Gradual aggregation followed by precipitation of the complex 
in buffered samples was seen. In vitro biological studies are usually performed in cell 
culture medium complemented with foetal calf serum (containing albumin as most 
abundant protein), hence, information about the solubility of the compound in these 
conditions is required. It was found that RPMI 1640 cell culture medium (non-
complemented) could not hinder the precipitation of the complex (Figure S6/A). 
Therefore, interaction with the most abundant serum protein, albumin, was further 
investigated. In order to assay the albumin binding, samples were prepared both in 
phosphate and HEPES buffers (20 mM, ccomplex = 13.8 M; 2% ethanol (v/v); pH = 
7.40; T = 25 °C) with a protein-to-metal complex ratio of 6:1. The presence of the 
protein prevents precipitation of the metal complex in both media (Figure S6/B) 
confirming the binding interaction between human serum albumin (HSA) and 
[Ru(DIP)2(mal)](PF6). The binding to the protein seems to take place via 
intermolecular bonding, since no release of maltol or 4,7-diphenyl-1,10-phenantroline 
could be detected by UV-vis spectroscopy in ultrafiltration experiments (Figure S7). 
HSA possesses hydrophobic binding pockets to accommodate small molecules, and 
binding at sites I and II of HSA was investigated spectrofluorimetrically due to the 
available site marker probe molecules (see details in Section S7). Interaction at site I 
was studied via the standard approach, namely following the quenching of the single 
Trp amino acid of HSA.[60] Determination of binding data was hindered by the complete 
overlapping of the weak intrinsic fluorescence of the metal complex with the protein 
Trp emission band (see Figure S8). The measured intensity upon the addition of the 
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complex to the protein is not the sum of the intensities of the complex and HSA (thus 
not additive), which indicates the binding interaction at site I and an upper limit of 
binding constant logK’ < 4.0 could be estimated at this site.  
Binding at site II was followed via site marker displacement experiment using 
dansylglycine (DG) as marker. DG was gradually displaced by [Ru(DIP)2(mal)](PF6) 
at site II (Figure 2). Calculated binding constant logK’ (site II) = 4.3 ± 0.1 reveals 
moderate-to-weak binding affinity of [Ru(DIP)2(mal)](PF6) at site II. For comparison, 
the fast intermolecular binding of KP1339 was characterized by binding constants of 
logK’ = 5.71 and 5.32 at site I and site II on HSA respectively.[61] Binding constants 
reported here for [Ru(DIP)2(mal)](PF6) are at least one order of magnitude lower when 
compared to those of KP1339. It is worth to highlight that, in the case of KP1339, it is 
quite possible that a metabolite (or several metabolites) binds to the protein, rather than 
the parent complex. In fact, in 2016, Keppler and co-workers reported the X-ray 
structure of "KP1019 bound to HSA".[62] Under the soaking conditions used to grow 
the crystals (24 h, phosphate buffer solution pH 7.4, 20 °C), two naked Ru ions were 
found coordinated at two histidine residues located within the hydrophobic binding 
pockets of the protein.[62] Conversely, our Ru(II) complex is coordinatively saturated 
and much less likely to lose the chelating ligands, i.e. it is more suited to give non-
covalent interactions, as already observed for similar compounds.[63] Moreover, 
oxaliplatin, another well-known metal complex has a similar binding constant (logK’ 
= 4.17), although in this case the binding evidently takes place via coordination bond.[64] 
Taking into account the high serum concentration of HSA (ca. 630 μM), and based on 
the determined binding constants, a considerable albumin binding (92-95%) of the 
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complex can be assumed at physiologically relevant conditions (1-50 μM complex 
concentration).  
 
 
Figure 2. Fluorescence emission spectra obtained by the titration of HSA–DG (1:1) 
with [Ru(DIP)2(mal)](PF6) (A); and measured (dots) and calculated (dashed line) 
intensity values at 490 nm (B). Blue dotted line denotes the emission of free DG. {cHSA 
= cDG 2 M; ccomp = 0–24 μM; λEX = 335 nm; pH = 7.40 (20 mM phosphate buffer); < 
2% ethanol; T = 25 C}. 
 
All in all, according to our results [Ru(DIP)2(mal)](PF6) binds to HSA via 
intermolecular interactions at least at the two hydrophobic sites: I and II. Albumin 
binding prevents precipitation of the metal complex in aqueous solution. 
 
Stability Studies in Human Plasma 
Next, to assess the behaviour of [Ru(DIP)2(mal)](PF6) under physiological conditions, 
its stability in human plasma was investigated by Ultra Performance Liquid 
Chromatography (UPLC) following a procedure already established by our group.[65] 
[Ru(DIP)2(mal)](PF6) (0.12 mM) was incubated in human plasma up to 96 h at 37°C 
using caffeine (1.92 mM) as an internal standard.[66] The UV traces of the UPLC 
analysis at different incubation times are shown in Figure S9a. When the concentration 
of [Ru(DIP)2(mal)](PF6) was normalized with respect to the internal standard and 
plotted against time (Figure S9b), no clear decomposition was observed in the first 24 
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h, whereas a linear decrease in concentration started thereafter. Based on these changes 
the half-life of [Ru(DIP)2(mal)](PF6) could be estimated to be of approximately 48 h 
under these conditions.  
   
Cytotoxicity Studies and Cell Death Mechanism 
After assessment of stability in solution, [Ru(DIP)2(mal)](PF6) biological activity was 
investigated. The first step was to evaluate the cytotoxicity in 2D cell culture models, 
comprising HeLa (human cervical adenocarcinoma), A2780 (human ovarian 
carcinoma), A2780 cis (human cisplatin resistant ovarian carcinoma), A2780 ADR 
(human doxorubicin resistant ovarian carcinoma), CT-26 (mouse colon 
adenocarcinoma), CT-26 LUC (mouse colon adenocarcinoma stably expressing 
luciferase) and RPE-1 (human normal retina pigmented epithelial) cell lines and using 
a fluorometric cell viability assay (single graphs available in Figures S10).[67] In this 
study, doxorubicin and cisplatin were tested in the same cell lines and used as positive 
controls.[68],[69] Cytotoxicity of the RuCl2(DIP)2 precursor and maltol ligand were also 
determined as additional controls. IC50 values of the tested compounds are reported in 
Table 1. The cytotoxicity of [Ru(DIP)2(mal)](PF6) was found very high and 
comparable to what previously observed for [Ru(DIP)2(sq)](PF6)[17] in all cell lines 
tested in this study. The IC50 values obtained are in the high nanomolar concentration 
range with the exception of the one determined on the doxorubicin-resistant cell line 
(IC50 = 2.86 μM). The RuCl2(DIP)2 precursor displays much lower cytotoxicity, while 
maltol, as expected, is non-toxic.[34],[35] [Ru(DIP)2(mal)](PF6) exerts an overall activity 
comparable to doxorubicin in all cell lines tested. Interestingly, its cytotoxicity against 
the cisplatin-resistant cell line is more than 40 times higher than that of cisplatin (IC50 
= 0.42 μM vs. 18.33 μM for [Ru(DIP)2(mal)](PF6) and cisplatin, respectively).  
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Table 1. IC50 values for [Ru(DIP)2(mal)](PF6), cisplatin, doxorubicin, 
[Ru(DIP)2(sq)](PF6), RuCl2(DIP)2 and maltol in different cell lines (48 h). 
IC50 (μM) HeLa A2780 A2780 ADR 
A2780 
cis CT-26 
CT-26 
LUC RPE-1 
Cisplatin* 9.28 ± 0.20 
4.00 ± 
0.76 
8.32 ± 
0.71 
18.33 ± 
2.92 
2.60 ± 
0.18 
2.42 ± 
0.23 
30.24 ± 
5.11 
Doxorubicin* 0.34 ± 0.02 
0.19 ± 
0.03 
5.94 ± 
0.58 
0.54 ± 
0.04 
0.082 ± 
0.003 
0.18 ± 
0.006 
0.89 ± 
0.17 
[Ru(DIP)2(sq)](P
F6)* 
0.50 ± 
0.01 
0.67 ± 
0.04 
4.13 ± 
0.2 
0.45 ± 
0.03 
1.00 ± 
0.03 
1.51 ± 
0.14 
0.90 ± 
0.04 
[Ru(DIP)2(mal)]
(PF6) 
0.45 ± 
0.04 
0.74 ± 
0.05 
2.86 ± 
0.3 
0.42 ± 
0.01 
0.61 ± 
0.02 
0.72 ± 
0.07 
0.86 ± 
0.04 
RuCl2(DIP)2* 15.03 ± 0.4 
4.69 ± 
0.14 
78.27 ± 
4.9 
6.36 ± 
0.57 
9.20 ± 
1.22 
6.65 ± 
0.5 
3.13 ± 
0.07 
Maltol 74.01 ± 14.6 >100 >100 >100 >100 >100 >100 
* Values taken from [[17]] We, however, note that these experiments were performed on the same days. 
Despite its promising activity, [Ru(DIP)2(mal)](PF6) did not display any selectivity 
towards cancer cells. This shortcoming is often faced in medicinal chemistry and it 
could be improved by the introduction of a targeting moiety. Therefore we decided to 
further investigate its biological activity by using a MCTS model.[70] 3D cultured cells 
are recognised as important research tools for their ability to resemble the 
pathophysiologic environment of the tumor tissue and,[71]–[73] along with the 2D model 
system, they allow for a better estimation of in vivo antitumour efficacy of 
compounds.[70],[72] The cytotoxicity of [Ru(DIP)2(mal)](PF6), its RuCl2(DIP)2 
precursor, [Ru(DIP)2(sq)](PF6), and the maltol ligand were tested via a luminescent 
cell viability assay in HeLa MCTS (single graphs are availabe in Figure S11). Cisplatin 
and doxorubicin were also tested in the same conditions as positive controls (Figure 
S11).[71],[73] The IC50 values of the tested compounds are reported in Table 2. 
[Ru(DIP)2(mal)](PF6) preserves the high cytotoxicity observed in the monolayer 
model with an IC50 value more than 2 times lower than cisplatin or doxorubicin (IC50 ~ 
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17 µM, 47 µM and 39 µM respectively), and comparable to that of 
[Ru(DIP)2(sq)](PF6). The RuCl2(DIP)2 precursor showed a cytotoxicity comparable 
to cisplatin while the maltol ligand was proven to be non-toxic also in this model.  
Table 2. IC50 values for [Ru(DIP)2(mal)](PF6), cisplatin, doxorubicin, RuCl2(DIP)2 
and maltol in multicellular HeLa cancer cell spheroids.  
IC50 
(μM) Cisplatin* 
Doxorubici
n* 
[Ru(DIP)2(s
q)](PF6)* [Ru(DIP)2(mal)](PF6) 
RuCl2(DIP)
2* Maltol 
HeLa 
MCTS 46.49 ± 4.18 38.59 ± 0.43 
14.11 ± 0.09 17.00 ± 0.73 59.84 ± 3.05 >100 
* Values taken from [[17]]. Notably, these experiments were performed on the same days. 
 
Next, the size of treated MCTS was studied to evaluate the time dependent effect of the 
[Ru(DIP)2(mal)](PF6). Growth kinetics of treated spheroids was monitored by changes 
in spheroids diameter in agreement with previously published protocols.[71],[73]–[75] 
Briefly 400 µm HeLa MCTS were treated with different concentrations of 
[Ru(DIP)2(mal)](PF6), and their diameter was checked every three days (Figure 3). Of 
note, when the washing step was performed, half of the medium was removed and 
replaced with fresh one, diluting twice the quantity of the compound in each well. At 
all concentrations tested, [Ru(DIP)2(mal)](PF6) caused a significant decrease in the 
size of the spheroids. Strikingly, this effect was still dominant even after 13 days of 
treatment.  
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Figure 3. Changes in growth kinetics of MCTS treated with [Ru(DIP)2(mal)](PF6) at 
different concentrations (1, 5, 10, 20, 25 and 30 µM). (a) Images collected at day 0 
(before treatment) and at day 3, 6, 9 and 13. b) MCTSs diameter measured at different 
time points. Blue-dotted line indicates the day of seeding, red-dotted line indicates the 
day of treatment while green-dotted lines indicate the days of washing. 
 
In summary, [Ru(DIP)2(mal)](PF6) showed high cytotoxicity in 2D and 3D models, as 
well as prolonged effect on the spheroids growth. These promising results encouraged 
further evaluation of the mechanism of cell death caused by the complex. To determine 
whether cell death occurs by apoptosis or by necrosis process, HeLa cells were analysed 
by flow cytometry using the Annexin V and PI (propidium iodide) staining method. In 
this experiment, staurosporin, a known apoptosis inducer, was used as positive 
control.[76] 4 h incubation of HeLa cells with [Ru(DIP)2(mal)](PF6) (10 μM) induced 
considerable cell death, mostly through apoptosis. Longer incubation of the cells with 
the complex (24 h) significantly increased the number of cells undergoing apoptotic 
cell death. In comparison with staurosporin, only a small population of the cells was PI 
positive after 24 h treatment with [Ru(DIP)2(mal)](PF6). Since PI is a vital stain (viable 
cells with intact membranes will exclude PI), this small population might refer either 
to dead cells or cells undergoing necrosis. Annexin V and PI staining confirmed that 
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[Ru(DIP)2(mal)](PF6) induces mostly apoptotic cell death in treated HeLa cells. 
Specific cell populations are shown in Figures 4 and S12.  
 
Figure 4. Annexin V and PI staining in HeLa cells treated with [Ru(DIP)2(mal)](PF6) 
(10 μM) and staurosporine (1 μM) at different time points. The fourth quadrant 
represents living cells (Annexin V, PI negative), first one early apoptotic cells (Annexin 
V positive, PI negative), second late apoptotic (Annexin and PI positive) and third 
necrotic or dead cells (Annexin V negative and PI positive). 
 
Cellular Uptake, Biodistribution, and DNA Metalation. 
To obtain more insights about the mode of action of [Ru(DIP)2(mal)](PF6), it is 
essential to understand its cellular and subcellular accumulation as much as its 
mechanism of uptake. For this purpose, inductively coupled plasma mass spectrometry 
(ICP-MS) was utilised. Working concentrations and incubation times were chosen to 
avoid extended cell mass loss due to the high cytotoxicity of the complex but 
considering a ruthenium final amount that could allow determination of the metal 
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content. However, the working conditions (5 µM treatment for 2 h), in agreement with 
literature data, allowed for a minor accumulation of the drug cisplatin used as 
control.[77],[78] [Ru(DIP)2(mal)](PF6) accumulation in HeLa cells was found to be 
higher than cisplatin used as control and almost three times higher than the 
[Ru(DIP)2(sq)](PF6) analogue previously reported by our group (Figure 5a).[17] This 
could be explained by the different mechanism of cellular uptake associated to the two 
complexes. To fully understand the uptake mechanism, HeLa cells were pre-treated or 
kept at different temperatures to determine if the uptake mechanism is passive or active. 
For this purpose, low temperature (4ºC should slow down passive diffusion as well as 
ATP required transport) or treatments with active transport inhibitors was utilised. 2-
Deoxy-D-glucose and oligomycin block cellular metabolism (ATP production), 
chloroquine or NH4Cl imped endocytic pathways and tetraethylammonium chloride 
stops cation transporters. After pre-treatment, cells were incubated with the compound 
(2 h, 5 µM) and subsequently analysed via ICP-MS (Figure S13). Inhibition of active 
uptake mechanisms did not perturb accumulation of [Ru(DIP)2(mal)](PF6) in HeLa 
cells. These findings clearly suggest that passive transport is the only mechanism 
responsible for accumulation of [Ru(DIP)2(mal)](PF6) in HeLa cells, unlike 
[Ru(DIP)2(sq)](PF6), whose mechanism of uptake involves both active and passive 
transports.[17] Cellular fractionation experiments revealed the relative distribution of 
[Ru(DIP)2(mal)](PF6) among the different subcellular compartments (Figure 5b). 
Most of the complex was found in the nucleus, while a rather small fraction was 
detected in the cytoplasm, mitochondria and lysosomes. Similar cellular distribution 
was found for the [Ru(DIP)2(sq)](PF6).[17] The accumulation of a compound in the 
nucleus suggests DNA as one of the potential targets. Therefore, the reactivity of our 
compound towards DNA was further studied via DNA metalation experiment. HeLa 
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cells were treated for 2 h with 5 µM solutions of [Ru(DIP)2(mal)](PF6) or cisplatin 
(positive control). The genetic material was then extracted, and the amount of metal 
was determined by ICP-MS. Data are shown in Figure 5c in comparison to those 
obtained for the analogue [Ru(DIP)2(sq)](PF6) and cisplatin.[17] These data point to a 
significant interaction between DNA and [Ru(DIP)2(mal)](PF6), which is much higher 
than the one with cisplatin and comparable to the one with [Ru(DIP)2(sq)](PF6). It is 
worth noting that a preliminary study towards the understanding of the nature of the 
interaction between the complexes and a DNA model using UV-vis spectroscopy 
showed no coordinative interaction between [Ru(DIP)2(mal)](PF6) or 
[Ru(DIP)2(sq)](PF6) and guanosine over 5 days (See section 12 of the Supporting 
Information). 
 
Figure 5. ICP-MS uptake studies of [Ru(DIP)2(mal)](PF6) in HeLa cells  after 
treatment with tested compounds (5 µM, 2 h). Data are presented as the mean ± SD of 
at least 3 biological repeats. (a) Total cellular uptake in comparison with 
[Ru(DIP)2(sq)](PF6) and cisplatin. Unpaired t-test between [Ru(DIP)2(sq)](PF6) and 
[Ru(DIP)2(mal)](PF6), p= 0.0005. (b) Intracellular distribution in comparison with 
[Ru(DIP)2(sq)](PF6)  and cisplatin. Unpaired t-test between [Ru(DIP)2(sq)](PF6) and 
[Ru(DIP)2(mal)](PF6), pnucleus= 0.508, pcytoplasm= 0.290, pmitochondria= 0.600, plysosomes= 
0.460. (c) DNA metalation in comparison with [Ru(DIP)2(sq)](PF6) and cisplatin. All 
data related to [Ru(DIP)2(sq)](PF6) were previously reported by our group.[17] We, 
however, note that these experiments were performed on the same days. 
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JC-1 Mitochondrial Membrane Potential Test and Metabolic Studies. 
The accumulation of [Ru(DIP)2(mal)](PF6) in mitochondria suggested studies on 
possible effects of the compound on mitochondrial function. To this end, we used JC-
1, a green fluorescent monomer at low mitochondrial membrane potential (MMP) that 
aggregates and emits red fluorescence at higher potential.[79] MMP is a key factor of 
the mitochondrial function due to its direct correlation to oxidative phosphorylation.[80] 
Figure 6a shows the red fluorescence signal observed in HeLa cells upon 24 h treatment 
with [Ru(DIP)2(mal)](PF6), FCCP (carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone, an uncoupling agent used as positive control),[81] 
and DMSO (vehicle control). An uncoupling agent is a molecule that inhibits the 
coupling between reactions of ATP synthesis and the electron transport chain leading 
to a disruption of oxidative phosphorylation in mitochondria.[82] Untreated cells are 
shown as a negative control. A significant concentration-dependent decrease in the 
fluorescence signal was observed upon treatment with [Ru(DIP)2(mal)](PF6) (from 0.1 
µM to 0.6 µM). At the IC50 value (0.5 µM, marked in red in Figure 6a), the MMP 
decrease was comparable to that obtained for the positive control. However, it is 
important to take into consideration that a dramatic drop in MMP could be triggered by 
ongoing apoptosis.[81] These findings strongly suggest a contribution of impaired MMP 
to the cell death mechanism and inspired further studies on mitochondrial metabolism 
(i.e. oxidative phosphorylation) in HeLa cells. For this purpose, the Mito stress test was 
performed using Seahorse XF Analyzer. The low basal respiration observed in cells 
treated with [Ru(DIP)2(mal)](PF6) in comparison to untreated cells, clearly 
demonstrates a severe impairment of mitochondrial respiration. In contrast, the 
RuCl2(DIP)2 precursor and the maltol ligand did not remarkably affect this process. 
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Additionally, [Ru(DIP)2(mal)](PF6) caused a loss in the capacity of the mitochondrial 
membrane to restore the proton balance when treated with an uncoupling agent (FCCP) 
and inhibited ATP production (Figure 6b and Figure S14). Taken together, these data 
demonstrate that [Ru(DIP)2(mal)](PF6) treatment causes complete disruption of 
mitochondrial respiration in HeLa cells. Furthermore, we investigated effects on other 
metabolic pathways, such as glycolysis, and the possible metabolic modulation of the 
three primary fuel pathways (involving glucose, glutamine or fatty acids as substrates) 
using a Seahorse XF Analyzer. The cytosolic process of glycolysis was not affected by 
[Ru(DIP)2(mal)](PF6) or its precursor (Figure S15). Effects on three primary fuel 
pathways could not be determined due to very low oxygen consumption rate in cells 
treated with [Ru(DIP)2(mal)](PF6) (Figure S16). Metabolic studies pointed to a 
substantial difference in the mode of action of [Ru(DIP)2(mal)](PF6) and the 
chemotherapeutic drug cisplatin. The latter is known to interfere with DNA replication 
and does not affect mitochondrial metabolism. [Ru(DIP)2(mal)](PF6), on the other 
hand, clearly demonstrated that the mitochondrial disfunction is significantly involved 
in its mode of action.  
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Figure 6. a) Fluorescence signal of JC-1 dye detected in HeLa cells treated for 24 h with 
different concentrations of [Ru(DIP)2(mal)](PF6) (from 0.1 µM to 0.6 µM). The bar 
marked in red indicates the IC50 concentration (0.5 µM). FCCP was used as positive 
control, cisplatin and DMSO (1%) were used as negative controls. b) Mito Stress Test 
profile after 24 h treatment; the graph displays oxygen consumption rate changes after 
treatment with specific electron transport chain inhibitors. Oligomycin (inhibitor of 
ATP synthase (complex V)), FCCP (uncoupling agent), Antimycin-A (complex III 
inhibitor) and Rotenone (complex I inhibitor). 
 
Conclusions  
Following the development of the potential anticancer agent [Ru(DIP)2(sq)](PF6) by 
our group, here we report synthesis and biological evaluation of an analogue complex, 
namely [Ru(DIP)2(mal)](PF6), containing the FDA-approved, flavour-enhancing 
agent, maltol. It was found that the compound is stable at room temperature in DMSO 
over 42 h and has an half-life of 48 h in human plasma. Although the complex exhibits 
poor water solubility, the measurements in human plasma as well as in supplemented 
media were made possible by the presence of human serum albumin. In the course of 
this study, we demonstrated that [Ru(DIP)2(mal)](PF6) binds to HSA via 
intermolecular interactions at least at the two hydrophobic sites (I and II), preventing 
10.1002/chem.201904877
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
22 
 
precipitation of the metal complex in aqueous solution. Studies performed on several 
cancerous cell lines in cellular monolayer culture and on HeLa MCTS indicated 
remarkable activity by [Ru(DIP)2(mal)](PF6), comparable to doxorubicin and much 
higher than the approved drug cisplatin. It is worth nothing that [Ru(DIP)2(mal)](PF6) 
cytotoxicity against the cisplatin-resistant cell line is more than 40 times higher than 
that of cisplatin (IC50 = 0.42 μM vs. 18.33 μM for [Ru(DIP)2(mal)](PF6) and cisplatin, 
respectively) in 2D model cultures. Moreover, HeLa MCTS treated with different 
concentrations of [Ru(DIP)2(mal)](PF6) demonstrated a significant decrease in size, 
even after 13 days of a single treatment. Unfortunately [Ru(DIP)2(mal)](PF6) did not 
exhibit any selectivity against cancerous or normal cell lines. This particular drawback 
could be overcome in future studies by conjugation of the complex to a targeting 
moiety. Cellular uptake studies showed efficient cellular accumulation of the 
compound, when compared to cisplatin or the analogue [Ru(DIP)2(sq)](PF6), through 
a passive transport mechanism. Deeper investigations on [Ru(DIP)2(mal)](PF6) mode 
of action by means of cellular fractionation, showed the nucleus as main accumulation 
site. DNA metalation studies confirmed the interaction between [Ru(DIP)2(mal)](PF6) 
and DNA, suggesting the latter as another potential target. Mitochondrial disfunction 
was assessed through a mito-stress test (Seahorse technology) and changes in MMP 
(JC-1 staining): both approaches led to establish a conclusive contribution of impaired 
mitochondria metabolism in the mode of action of [Ru(DIP)2(mal)](PF6). These 
findings together with what previously reported on the activity of [Ru(DIP)2(sq)](PF6), 
emphasise the outstanding potential of this class of compounds, which should be taken 
into account from scientists involved in the search of new chemotherapeutic agents. 
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Experimental Section  
Materials.  
All chemicals were either of reagent or analytical grade and used as purchased from 
commercial sources without additional purification. RuCl3 hydrate was provided by 
I2CNS, 4,7-Diphenyl-1,10-phenanthroline, LiCl (anhydrous, 99%), and maltol by Alfa 
Aesar, tetrabutylammonium hexafluorophosphate by Sigma-Aldrich. All solvents were 
purchased of analytical, or HPLC grade. When necessary, solvents were degassed by 
purging with dry, oxygen-free nitrogen for at least 30 min before use. 
Instrumentation and methods.  
Amber glass or clear glassware wrapped in tin foil was used when protection from light 
was necessary. Schlenk glassware and a vacuum line were employed when reactions 
sensitive to moisture/oxygen had to be performed under nitrogen atmosphere. Thin 
layer chromatography (TLC) was performed using silica gel 60 F-254 (Merck) plates 
with detection of spots being achieved by exposure to UV light. Column 
chromatography was done using Silica gel 60-200 µm (VWR). Eluent mixtures are 
expressed as volume to volume (v/v) ratios. 1H and 13C NMR spectra were measured 
on Bruker Avance III HD 400 MHz or Bruker Avance Neo 500 MHz spectrometers 
using the signal of the deuterated solvent as an internal standard.[83] The chemical shifts 
(δ) are reported in ppm (parts per million) relative to tetramethylsilane (TMS) or signals 
from the residual protons of deuterated solvents. Coupling constants J are given in 
Hertz (Hz). The abbreviation for the peaks multiplicity is s (singlet), d (doublet), dd 
(doublet of doublet), m (multiplet). ESI-HRMS experiments were carried out using a 
LTQ-Orbitrap XL from Thermo Scientific (Thermo Fisher Scientific, Courtaboeuf, 
France) and operated in positive ionization mode, with a spray voltage at 3.6 kV. Sheath 
and auxiliary gas were set at a flow rate of 5 and 0 arbitrary units (a.u.), respectively. 
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The voltages applied were 40 and 100 V for the ion transfer capillary and the tube lens, 
respectively. The ion transfer capillary was held at 275°C. Detection was achieved in 
the Orbitrap with a resolution set to 100,000 (at m/z 400) and a m/z range between 200-
2000 in profile mode. Spectrum was analysed using the acquisition software XCalibur 
2.1 (Thermo Fisher Scientific, Courtaboeuf, France).  The automatic gain control 
(AGC) allowed accumulation of up to 2.105 ions for FTMS scans, Maximum injection 
time was set to 300 ms and 1 µscan was acquired. 5 µL was injected using a Thermo 
Finnigan Surveyor HPLC system (Thermo Fisher Scientific, Courtaboeuf, France) with 
a continuous infusion of methanol at 100 µLmin-1. Elemental analysis was performed 
at Science Centre, London Metropolitan University using Thermo Fisher (Carlo Erba) 
Flash 2000 Elemental Analyser, configured for %CHN. IR spectra were recorded with 
SpectrumTwo FTIR Spectrometer (Perkin–Elmer) equipped with a Specac Golden 
GateTM ATR (attenuated total reflection) accessory; applied as neat samples; 1/λ in 
cm–1. Stability in human plasma was performed on HPLC (VWR Hitachi Chromaster 
system) and a Macherey Nager EC 250/3 Nucleosil 100-5 C18 column. UV absorption 
was measured at 275 nm and the runs (flow rate 0.6 mLmin-1) were performed with a 
linear gradient of A (distilled water containing 0.1% (v/v) TFA) and B (acetonitrile, 
Sigma-Aldrich HPLC grade): t = 0 min, 5% B; t = 0.5 min, 5% B; t = 1.5 min, 100% 
B; t = 2 min, 100% B. Ruthenation of the DNA was performed using a High-Resolution 
ICP-MS Element II from ThermoScientific located within the Environmental 
Biogeochemistry team of the Institut de Physique du Globe de Paris. This ICP-MS 
enables working in different resolution modes (LR=400, MR=4000 and HR=10000) 
for a better discrimination between elements of interest and interferences.[84] For the 
metabolic studies Seahorse XFe96 Analyser by Agilent Technologies was used. 
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RuCl2(DMSO)4 was synthesised following an adapted literature procedure.[52] 
Spectroscopic data (1H NMR) was in agreement with literature.[52]  
 
Synthesis and characterization. 
Ru(DIP)2Cl2. The complex was synthesised following an adapted literature 
procedure.[53] A mixture of RuCl2(DMSO)4 (3.0 g, 6.19 mmol), 4,7-diphenyl-1,10-
phenanthroline (DIP, 4.11 g, 12.38 mmol) and LiCl (2.0 g, 47.18 mmol) dissolved in 
DMF (100 mL) was refluxed for 24 h. After cooling to r.t. the solvent was reduced in 
vacuo to 8 mL and 350 mL of acetone were added. After overnight storage at -20 °C 
the deep purple solid was removed by filtration with a Buchner funnel and washed with 
cold acetone and Et2O. Ru(DIP)2Cl2 was then collected, dried and purified by silica gel 
chromatography (DCM/MeOH 97:3 rf 0.4) to afford the complex in 52% yield (2.71 g, 
3.23 mmol,) which purity was confirmed by microanalysis. Spectroscopic data (1H 
NMR) were in agreement with literature.[53] 
[Ru(DIP)2(mal)](PF6)  
Ru(DIP)2Cl2 (0.150 g, 0.18 mmol) and aq. NaOH (0.28 mL, 1 M) were dissolved in 
ethanol (18 mL). The solution was degassed for 30 min and maltol (3-Hydroxy-2-
methyl-4H-pyran-4-one) (0.036 g, 0.29 mmol) was added. The mixture was heated to 
reflux for 3 h under N2 atmosphere and protected from light. After cooling to r.t., H2O 
(200 mL) and NH4PF6 (1 g, 6 mmol) were added. The mixture was stored overnight in 
the refrigerator (4 °C). The precipitate was collected on a Buchner funnel, washed with 
H2O (3 × 50 mL) and Et2O (3 × 50 mL). The solid was sonicated with Et2O or Heptane 
(10 mL) for 10 min and then centrifuged. This procedure was repeated three times for 
each solvent. The solid was eventually dried under vacuum to deliver a clean product 
as the PF6 salt (0.17 g, 0.16 mmol, 90%). IR (Golden Gate, cm-1): 1590w, 1545w, 
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1490w, 1465w, 1445w, 1415w, 1400w, 1275w, 1205w, 1085w, 1025w, 915w, 830s, 
765s, 735m, 700s. 1H NMR (400 MHz, CD2Cl2): δ/ppm = 9.49 (d, J = 5.4 Hz, 1H), 9.33 
(d, J = 5.5 Hz, 1H), 8.23 (dd, J = 9.4, 4.6 Hz, 2H), 8.13 (dd, J = 9.4, 1.1 Hz, 2H), 8.04 
(d, J = 5.6 Hz, 2H), 7.98 (dd, J = 13.5, 5.4 Hz, 2H), 7.78 – 7.60 (m, 11H), 7.59 – 7.47 
(m, 10H), 7.33 (dd, J = 5.6, 3.0 Hz, 2H), 6.54 (d, J = 5.1 Hz, 1H), 2.37 (s, 3H). 13C 
NMR (125 MHz, CD2Cl3): δ/ppm = 185.00, 159.02, 155.49, 154.10, 154.01, 151.75, 
151.47, 151.06, 150.64, 150.17, 149.98, 149.92, 147.66, 147.13, 146.01, 145.71, 
136.50, 136.47, 136.23, 136.20, 130.15, 129.86, 129.81, 129.47, 129.44, 129.28, 
129.21, 129.10, 128.78, 128.61, 128.55, 128.46, 125.96, 125.82, 125.77, 125.77, 
125.69, 125.51, 125.25, 125.05, 112.40, 29.84. HRMS (ESI+): m/z 891.19042 [M - 
PF6]+. Elemental Analysis: calcd. for C54H39F6N4O4PRu = C, 61.54; H, 3.73; N, 5.32. 
Found = C, 61.53; H, 3.38; N, 5.17. 
 
Electrochemical Measurements. 
Electrochemical experiments were carried out with a conventional three-electrodes cell 
(solution volume of 15 mL) and a PC-controlled potentiostat/galvanostat (Princeton 
Applied Research Inc. model 263A). The working electrode was a vitreous carbon 
electrode from Origalys (France) exposing a geometrical area of 0.071 cm2 and 
mounted in Teflon®. The electrode was polished before each experiment with 3 and 0.3 
m alumina pastes followed by extensive rinsing with ultra-pure Milli-Q water. A 
platinum wire was used as counter electrode and saturated calomel electrode, SCE, as 
reference electrode. Electrolytic solutions, DMF containing tetrabutylammonium 
hexafluoroborate 0.1M (TBAPF6, Aldrich, +99 %) as supporting electrolyte, were 
routinely deoxygenated by argon bubbling. All the potential values are given versus the 
calomel saturated electrode SCE and recalculated versus Me10Fc0/+ potential value.  
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DMSO and Human Plasma stability studies. 
The stability in DMSO-d6 at room temperature was assessed by 1H NMR over 42 hours. 
The stability of the complex in human plasma at 37 °C was evaluated following an 
adapted procedure recently reported by our group.[85] Human plasma was provided by 
the Blutspendezentrum, Zurich, Switzerland. Caffeine was obtained from Sigma-
Aldrich and used as an internal standard.[66] Stock solutions of the complex (9.6 mM) 
in DMSO and caffeine (0.15 M) in H2O were prepared. For a typical experiment, an 
aliquot of 12.5 µL of each stock solution was added to the plasma solution (975 µL) to 
a total volume of 1000 µL and final concentration of 1.92 mM for caffeine and 0.12 
mM for the complex. The resulting plasma solution was incubated for 0, 1, 2, 4, 6, 24, 
48, 72 and 96 h at 37 °C with continuous and gentle shaking (ca. 600 rpm). The reaction 
was stopped by addition of 2 mL of MeOH, and the mixture was centrifuged for 45 min 
at 3500 rpm. The methanolic solution was filtered and analysed using HPLC and an 
injection volume of 6 µL.  
 
Stability of the complex in different solvents and at different conditions. 
Preparation of stock solutions: Human serum albumin (HSA as lyophilized powder 
with fatty acids), Na2HPO4, NaH2PO4, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) and danysylglycine (DG) were obtained from Sigma-Aldrich in puriss 
quality. Powdered RPMI 1640 cell culture medium without indicator for 1 L solution 
was a Sigma-Aldrich product as well. Milli-Q ultrapure water was used for sample 
preparations. HSA solution was freshly prepared before the experiments in 20 mM 
phosphate or in 20 mM HEPES buffer (pH = 7.40). Its concentration was estimated 
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from its UV absorption: 280 nm(HSA) = 36850 M−1cm−1.[86] Stock solutions of the 
complex were freshly prepared every day in ethanol in 1-2 mM concentration. 
1H NMR measurements: 1H NMR spectroscopic studies were carried out on a Bruker 
Avance III HD Ascend 500 Plus instrument. The metal complex was dissolved in 
methanol-d4 in 3.3 mM concentration. Samples prepared in methanol-d4, RPMI 1640 
medium or in 20 mM phosphate buffer (pH = 7.40) contained 1 mM metal complex and 
30% (v/v) methanol-d4. Spectra for water containing samples were recorded with the 
WATERGATE water suppression pulse scheme using DSS internal standard.  
UV-Vis spectrophotometry and ultrafiltration: An Agilent Carry 8454 diode array 
spectrophotometer was utilized to record the UV–visible (UV–vis) spectra in the 
interval 190–1100 nm. The path length (l) was 1 cm. Aqueous stability of the complex 
was followed in 20 mM phosphate buffer (pH = 7.40), in 20 mM HEPES buffer (pH = 
7.40), in RPMI 1640 medium, in the presence of HSA, in ethanol, methanol and in pure 
water (pH ~ 8). Measurements on the protein binding of the complex were performed 
at fixed metal complex concentration (20 μM) and various protein-to-complex ratios 
(from 0.02:1 to 10:1) were applied.  
Spectrofluorometric studies: Samples were prepared in 20 mM phosphate or in 20 mM 
HEPES buffer (pH 7.40); spectra were recorded after 5 min incubation. Samples for 
quenching experiments contained 1 µM HSA and various HSA-to-metal complex ratios 
(from 1:0 to 1:15) were used. The excitation wavelength was 295 nm; the emission 
intensities were read in the range of 305 – 500 nm with 5 nm/5 nm slit widths. In the 
site marker displacement experiments, the HSA-to-DG ratio was 1:1 (2-2 μM) and the 
concentration of the metal complex was varied from 0 to 37 μM. The excitation 
wavelength was 335 nm and the emission intensity was collected in the range of 420 – 
600 nm with 5 nm/10 nm slit widths. The conditional binding constant for the site II 
10.1002/chem.201904877
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
29 
 
binding of the complex was calculated with the computer program HypSpec[87] as 
described in our previous works.[30],[61] Corrections for self-absorbance and inner filter 
effect were done.[60] 
 
Cell culture. 
HeLa and CT-26 cell lines were grown in DMEM media (Gibco). CT-26 LUC cell line 
was cultured in DMEM media (Gibco) supplemented with 1.6 mg/mL of Genticin. 
RPE-1 cell line was grown and maintained in DMEM/F-12 media (Gibco). A2780, 
A2780 cis, A2780 ADR cell lines were cultured in RPMI 1640 media (Gibco). The 
resistance of A2780 cis was maintained by cisplatin treatment (1µM) for one week 
every month. Cells were used in the assays one week after the end of the treatment, in 
order to avoid interferring results. The resistance of A2780 ADR was maintained by 
doxorubicin treatment (0.1 µM) once a week. Cells were used in the assays after three 
days post doxorubicin treatment in order to avoid interferring results. All cell lines were 
complemented with 10% of fetal calf serum (Gibco) and 100 U/mL penicillin-
streptomycin mixture (Gibco) and maintained in humidified atmosphere at 37°C and 
5% of CO2. 
 
Cytotoxicity Assay using a 2D cellular model. 
Cytotoxicity of [Ru(DIP)2(mal)](PF6) and RuCl2(DIP)2 complexes was assessed by a 
fluorometric cell viability assay using Resazurin (ACROS Organics). Briefly, cells 
were seeded in triplicates in 96-well plates at a density of 4×103 cells/well in 100 μL. 
After 24 h, cells were treated with increasing concentrations of the ruthenium 
complexes. Dilutions for [Ru(DIP)2(mal)](PF6) and RuCl2(DIP)2 were prepared as 
follows: 2.5 mM stock in DMSO ([Ru(DIP)2(mal)](PF6)) or DMF (RuCl2(DIP)2) was 
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prepared, which was further diluted to 100 µM and filtered (0.22 µm filter VWR). After 
48 h incubation, the medium was removed and 100 μL of complete medium containing 
resazurin (0.2 mg/mL final concentration) was added. After 4 h of incubation at 37 °C, 
the fluorescence signal of resorufin product was read (ex: 540 nm em: 590 nm) in a 
SpectraMax M5 microplate Reader. IC50 values were then calculated using GraphPad 
Prism software. 
 
Generation of 3D HeLa MCTS. 
MCTS were cultured using ultra-low attachment 96 wells plates from Corning® (Fisher 
Scientific 15329740). HeLa cells were seeded at a density of 5000 cells per well in 200 
µL medium. The single cells would generate MCTS approximately 400 µm in diameter 
at day 4 with 37 °C and 5 % CO2. 
 
Treatment of 3D HeLa MCTS. 
After 4 days of growing at 37 °C and 5% CO2, HeLa MCTS were treated for 48 h by 
replacing half of the medium in the well with medium containing increasing 
concentration of compounds. For untreated reference MCTS, half of the medium was 
replaced by fresh medium only. Cytotoxicity was measured by quantification of ATP 
concentration with CellTiter-Glo® Cell viability kit (Promega, USA).  
 
HeLa MCTSs growth inhibition. 
MCTSs were grown and treated as described above. MCTSs sizes were observed under 
a light microscope and pictures were taken with an iPhone 6s thanks to a phone 
microscope adaptor. Before imaging, the plate was shaken, and half of the media was 
exchanged to remove dead cells. Images were recorded before treatment (day 0) and at 
10.1002/chem.201904877
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
31 
 
day 3, 6, 9 and 13 after treatment. Pictures were first processed using GIMP a cross-
platform image editor with a batch automation plug-in. The MCTSs sizes were then 
calculated with SpheroidSizer, a MATLAB-based and open-source software 
application to measure the size of tumour spheroids automatically and accurately. Data 
analysis was done using GraphPad Prism software. 
 
Annexin V / PI assay. 
Apoptosis and necrosis induction in HeLa cells treated with [Ru(DIP)2(mal)](PF6) was 
evaluated via an AnnexinV/PI staining assay using flow cytometry. Briefly, cells were 
seeded at density of 2×106 cells in 10 cm cell culture dish 24 h prior cell treatments. 
The medium was removed and replaced with 10 μM solution of complex 
[Ru(DIP)2(mal)](PF6) or 1 µm Staurosporin (positive control -Abcam Cat no.120056) 
and further incubated for 30 min, 4 h or 24 h. Cells were collected, washed twice with 
ice cold PBS and resuspended in 1x Annexin V binding buffer (10 x buffer 
composition: 0,1 M HEPES (pH 7.4), 1.4 M NaCl. 25 mM CaCl2). Samples were 
processed according to the manufacturer instructions (BD Scientific, cat no 556463 and 
556419) and analysed using ZE5 Biorad instrument at Cytometry Platform at Institute 
Curie. Data were analysed using the FlowJo software.  
 
Sample Preparation for cellular uptake. 
Cells were seeded at density of 2×106. Next day, cells were treated with 5 µM 
concentration of [Ru(DIP)2(mal)](PF6) or RuCl2(DIP)2. After 2 h, cells were 
collected, counted and snap frozen in liquid nitrogen and stored at -20 ºC. ICP-MS 
samples were prepared as follows: samples were digested using 70% nitric acid (1 mL, 
60 ºC, overnight). Samples were then further diluted 1:100 (1% HCl solution in MQ 
10.1002/chem.201904877
Ac
ce
pt
ed
 M
an
us
cr
ip
t
Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
32 
 
water) and analysed using ICP-MS. 
 
Sample Preparation for cellular fractionation. 
HeLa cells (passage 8) were seeded in three 15 cm2 cell culture dishes so that on the 
day of treatment cells were 90% confluent. On the day of treatment cells were incubated 
with the target complex at a concentration of 5 μM for 2 h. After that time, the medium 
was removed; cells were washed, collected and counted. After resuspension in cold 
PBS, the organelles were isolated via different protocols (one cell culture dish per 
isolation was used). 
Mitochondria isolation: To isolate mitochondria, a Mitochondria Isolation Kit (Cat. Nr: 
MITOISO2, Sigma Aldrich) was used according to the manufacturer procedure for 
isolation of mitochondria via homogenization method. 
Lysosome isolation: To isolate lysosomes, a Lysosome Isolation Kit (Cat. Nr: 
LYSISO1, Sigma Aldrich) was used, according to the manufacturer procedure for 
isolation of lysosomes via Option C. 
Nuclear and cytoplasm isolation: To isolate nuclear and cytoplasmic fractions, the 
ROCKLAND nuclear extract protocol was used.[88] Briefly cells were collected by 
centrifugation, resuspended in cytoplasmic extraction buffer and incubated on ice. The 
tubes were centrifuged and supernatant (CE) was removed. Pellets were washed with 
cytoplasmic extraction buffer without detergent and centrifuged. The pellet (NE) was 
resuspended in nuclear extraction buffer and incubated on ice. Both CE and NE were 
centrifuged. Supernatant from CE samples was indicated as cytoplasmic extract, 
whereas the pellet obtained from NE samples was indicated as nuclear extract.  
ICP-MS samples were prepared as follows: isolated cellular fractions were lyophilised 
and digested using 5 mL of 70% nitric acid (60 ºC, overnight). Samples were then 
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further diluted 1:200 –for nuclear pellet samples and 1:20 for all the other samples (1% 
HCl solution in MQ water) and analysed using ICP-MS. 
 
Sample preparation for studies on the mechanism of cellular uptake 
Samples were prepared as previously reported.[17] Briefly, HeLa cells were seeded at 
density of 2×106 and next day were pre-treated with corresponding inhibitors or kept at 
specific temperature for 1 h. Next, cells were washed with PBS and were incubated 
with 5 µM [Ru(DIP)2(mal)](PF6) for 2 h (low temperature sample was still kept at 4 
ºC). Afterwards cells were washed with PBS, collected, counted and snap frozen in 
liquid nitrogen. Pellets were stored at -20 ºC. ICP-MS samples were prepared as 
follows: samples were digested using 70% nitric acid (1 mL, 60 ºC, overnight), further 
diluted 1:100 (1% HCl solution in MQ water) and analysed using ICP-MS. 
 
DNA metalation of HeLa cells. 
Cells were seeded at density of 2 x 106. The following day, cells were treated with 5 
µM concentration of [Ru(DIP)2(mal)](PF6) or cisplatin. After 2 h, cells were collected, 
snap frozen in liquid nitrogen and stored at -20 ºC. The following day, DNA was 
extracted using a PureLink™ Genomic DNA Mini Kit (Invitrogen). DNA purity was 
checked by absorbance measurements at 260 and 280 nm. Concentrations of genomic 
DNA were calculated assuming that one absorbance unit equals 50 µg/mL. ICP-MS 
samples were prepared as follows: samples were digested using 70% nitric acid (60 ºC, 
overnight) in 1:1.6 DNA to acid volume ratio. Samples were then further diluted 1:10 
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or 1:100 (1% HCl solution in MQ water) and analysed using ICP-MS. 
 
ICP-MS studies.  
Daily, prior to the analytical sequence, the instrument was first tuned to produce 
maximum sensitivity and stability while also maintaining low uranium oxide formation 
(UO/U ≤ 5%). The data were treated as follow: intensities were converted into 
concentrations using uFREASI (user-FRiendly Elemental dAta proceSsIng ).[89] This 
software, made for HR-ICP-MS users community, is free and available on 
http://www.ipgp.fr/~tharaud/uFREASI. 
 
ICP-MS data analysis. 
Cellular uptake studies: The amount of metal detected in the cell samples was 
transformed from ppb into µg of metal. Data were subsequently normalised to the 
number of cells and expressed as µmol of metal/ amount of cells. 
Cellular fractionation: The amount of detected ruthenium in the cell samples was 
transformed from ppb into µg of ruthenium. Values were then normalised to the number 
of cells used for specific extraction. Due to low yield of lysosome extraction (only 
25%), the values obtained were multiplied by the factor of 4. Because of a low yield of 
mitochondria extraction (50% of the cells were homogenized), the values obtained for 
that organelle were multiplied by the factor of 2. Extraction protocols allow for the 
isolation of pure subcellular fractions. Therefore, the total amount of metal found in the 
cells was calculated summing the values obtained for the pure organelles. 
Mechanism of uptake: The amount of ruthenium detected in cell samples was 
transformed from ppb into µg of ruthenium and values obtained were normalised to the 
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number of cells used for specific treatment. The value for the ruthenium found in the 
37 ºC sample was used as a 100%.  
Cellular metalation: The amount of ruthenium detected in cell samples was 
transformed from ppb into µg of ruthenium and value obtained was normalised to the 
amount of DNA. 
 
JC-1 Mitochondrial Membrane Potential Test. 
HeLa cells were seeded at a density of 6000 cells / well in black 96 well-plates (Costar 
3916). The following day, cells were treated with different concentrations of 
[Ru(DIP)2(mal)](PF6) and RuCl2(DIP)2. After further 24 h, cells were treated 
according to the instructions of the JC-1 Mitochondrial Membrane Potential Assay Kit 
(Abcam, ab113850). The data were analysed using GraphPad Prism software. 
 
Metabolic Studies 
HeLa cells were seeded in Seahorse XFe96 well plates at a density of 30,000 cells / 
well in 80 μL medium. After 24 h, the medium was replaced with fresh medium and 
cisplatin (1 μM), doxorubicin (1 µM), maltol (1 μM), complex RuCl2(DIP)2 (1 μM) or 
complex [Ru(DIP)2(mal)](PF6) (1 μM) were added. After 24 h of incubation, the 
regular medium was removed, cells were washed thrice using Seahorse Base Media 
and incubated in a non-CO2 incubator at 37 °C for 1 h.  
Mito Stress Test: Mitostress assay was run using Oligomycin, 1 μM, FCCP 1 μM and 
mixture of Antimycin-A/ Rotenone 1 μM each in ports A, B and C respectively using 
Seahorse XFe96 Extracellular Flux Analyzer. 
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Glycolysis Stress Test: Glycolytic stress test was run using glucose (10 mM), 
Oligomycin (1 μM) and 2-Deoxyglucose (50 mM) in ports A, B and C respectively 
using Seahorse XFe96 Extracellular Flux Analyzer. 
Mito Fuel Flex Test: Fuel flex assay for the different fuel pathways viz. glucose, 
glutamine and fatty acid was studied by measuring the basal oxygen consumption rates 
and that after addition of the inhibitor of the target pathway in port A and a mixture of 
the inhibitors of the other two pathways in port B. This gave a measure of the 
dependency of the cells on a fuel pathway. To study the capacity of a certain fuel 
pathway, the sequence of addition of the inhibitors was reversed. In port A was added 
the mixture of inhibitors for the other pathways and in port B was added the inhibitor 
for the target pathway. UK-5099 (pyruvate dehydrogenase inhibitor, 20 μM) was used 
as an inhibitor for the glucose pathway. BPTES (selective inhibitor of Glutaminase 
GLS1, 30 μM) was used as an inhibitor for the glutamine pathway. Etomoxir (O-
carnitine palmitoyltransferase-1 (CPT-1) inhibitor, 40 μM) was used as an inhibitor for 
the fatty acid pathway. 
 
Associated Content 
Supporting Information 
The Supporting Information is at DOI: XXXXX. 
NMR spectra of [Ru(DIP)2(mal)](PF6) (Figure S1), voltammograms recorded by CV 
and with the use of RDE for [Ru(DIP)2(mal)](PF6) (Figure S2), electrochemical data 
for [Ru(DIP)2(mal)](PF6) (Table S1), overlap of 1H spectra of [Ru(DIP)2(mal)](PF6) 
in DMSO-d6 over 42h days (Figure S3), detailed investigation on the stability of the 
complex in different solvents and conditions (section 5, Figure S4, S5), RP-UPLC 
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traces of [Ru(DIP)2(mal)](PF6) (a) and percentage concentration of 
[Ru(DIP)2(mal)](PF6), normalized with respect to the internal standard and plotted 
against time (b) (Figure S6), more details on interaction with human serum albumin 
(section S7, Figures S7-S9), fluorometric cell viability assay (Figure S10), CellTiter 
Glo® viability Test (Figure S11), Cell Death Mechanism (Figure S12) cellular uptake 
mechanism of [Ru(DIP)2(mal)](PF6) (Figure S13), UV study of the interaction 
between RuCl2(DIP)2, [Ru(DIP)2(sq)](PF6) or [Ru(DIP)2(mal)](PF6) and guanosine 
(section S12, Figure S14), oxygen consumption rates and different respiration 
parameters in HeLa cells alone or after treatment with various test compounds (Figure 
S15), extracellular acidification rate and different parameters during glycolysis in HeLa 
cells alone or after treatment with various test compounds (Figure S16), Fuel flex assay 
in HeLa cells (Figure S17). 
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